Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies

Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'

November 9, 2017 9:56 AM EST

BMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from $38.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.

Analyst Gary Nachman notes a positive outlook on the shares, as the company reported earnings per share... More

UPDATE: H.C. Wainwright Assumes Pacira Pharmaceuticals (PCRX) at Buy

November 9, 2017 7:17 AM EST

(Updated - November 9, 2017 7:35 AM EST)

(updated to add analyst comment)

H.C. Wainwright assumes coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $52.00.

Analyst Oren Livnat comments "Slow and steady wins... More

Pacira Pharma (PCRX) Tops Q3 EPS by 17c, Miss on Revenues

November 8, 2017 7:37 AM EST

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.11, $0.17 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $70.04 million.

... More